Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo


Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges, oncologists and analysts say. The yet-to-be-published studies involve drugs in a new class designed to enable the body's immune system to fight cancer.



from Biotech News